Edition:
United States

Flex Pharma Inc (FLKS.OQ)

FLKS.OQ on NASDAQ Stock Exchange Global Market

3.82USD
4:00pm EDT
Change (% chg)

$-0.02 (-0.52%)
Prev Close
$3.84
Open
$3.84
Day's High
$3.89
Day's Low
$3.73
Volume
10,379
Avg. Vol
19,490
52-wk High
$8.95
52-wk Low
$2.68

Chart for

About

Flex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company's product candidates activate certain receptors in primary sensory neurons, which then act... (more)

Overall

Beta: 2.78
Market Cap(Mil.): $67.76
Shares Outstanding(Mil.): 17.97
Dividend: --
Yield (%): --

Financials

  FLKS.OQ Industry Sector
P/E (TTM): -- 223.30 32.53
EPS (TTM): -1.97 -- --
ROI: -92.69 -8.07 12.63
ROE: -92.80 -10.87 14.50

BRIEF-Flex Pharma Reports Q1 Loss Per Share $0.46

* Q1 EARNINGS PER SHARE VIEW $-0.49 -- THOMSON REUTERS I/B/E/S

May 02 2018

BRIEF-Flex Pharma Reports Positive Topline Data From Exploratory Phase 2 Trial Of FLX-787 In Multiple Sclerosis

* FLEX PHARMA REPORTS POSITIVE TOPLINE DATA FROM EXPLORATORY PHASE 2 TRIAL OF FLX-787 IN MULTIPLE SCLEROSIS

Mar 26 2018

BRIEF-Flex Pharma Reports Q4 Loss Per Share $0.46

* EXPECTS TO HAVE SUFFICIENT CAPITAL TO FUND ITS OPERATIONS TO MID 2019 Source text for Eikon: Further company coverage:

Mar 07 2018

BRIEF-Flex Pharma Engaged Investment Banking Firm To Assist With Consideration Of Strategic Alternatives For Co's Hotshot Consumer Product Business‍​

* FLEX PHARMA - ENGAGED INVESTMENT BANKING FIRM TO ASSIST WITH CONSIDERATION OF STRATEGIC ALTERNATIVES FOR CO'S HOTSHOT CONSUMER PRODUCT BUSINESS‍​ Source text: (http://bit.ly/2F0i8Tu) Further company coverage:

Jan 22 2018

BRIEF-Flex Pharma Inc - ‍Completed Enrollment In Its Phase 2 Exploratory Spasticity Study In Multiple Sclerosis With Approximately 50 Patients In Australia​

* FLEX PHARMA INC - ‍COMPLETED ENROLLMENT IN ITS PHASE 2 EXPLORATORY SPASTICITY STUDY IN MULTIPLE SCLEROSIS WITH APPROXIMATELY 50 PATIENTS IN AUSTRALIA​ Source text for Eikon: Further company coverage:

Nov 28 2017

Earnings vs. Estimates